Merck KGaA CEO Belén Garijo at the company's press conference on March 7, 2024 (Arne Dedert/picture alliance via Getty Images)
March 7, 2024 07:06 AM ESTUpdated 10:47 AM
Deals
R&D

Mer­ck KGaA to fo­cus on ‘ex­ter­nal in­no­va­tion’ as it ex­its BTK in­hibitor race

Ayisha Sharma

News Reporter

Mer­ck KGaA is re­vamp­ing its R&D ef­forts as it in­creas­es fo­cus on li­cens­ing deals rather than its in­ter­nal pipeline. Sev­er­al months af­ter a Phase III …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Jazz wins ap­proval for bis­pe­cif­ic in bil­iary tract can­cer

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

FDA ad­comm rais­es risk ques­tions on As­traZeneca’s An­dexxa

At Jef­feries, all that man­u­fac­tur­ers want to talk about is GLP-1s

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times